[A19-02] Ingenol mebutate (actinic keratosis) - Addendum to Commission A18-55
Last updated 21.03.2019
Commission awarded on 07.01.2019 by the Federal Joint Committee (G-BA).
Skin and hair
Patients with non-hyperkeratotic, non-hypertrophic actinic keratosis
Conclusion of dossier assessment A18-55 unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.